Current Status of New Anticoagulants in the Management of Venous Thromboembolism
Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and proph...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/856341 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551859376619520 |
|---|---|
| author | Roberto C. Montoya Ajeet Gajra |
| author_facet | Roberto C. Montoya Ajeet Gajra |
| author_sort | Roberto C. Montoya |
| collection | DOAJ |
| description | Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors. |
| format | Article |
| id | doaj-art-1a34cf81ec2f4bb494a34f9a0cef3330 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-1a34cf81ec2f4bb494a34f9a0cef33302025-02-03T06:00:13ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/856341856341Current Status of New Anticoagulants in the Management of Venous ThromboembolismRoberto C. Montoya0Ajeet Gajra1Division of Hematology-Oncology, Department of Medicine, SUNY Upstate Medical University, 750 E Adams St., Syracuse, NY 13210, USADivision of Hematology-Oncology, Department of Medicine, SUNY Upstate Medical University, 750 E Adams St., Syracuse, NY 13210, USAVenous Thromboembolism, manifested as deep venous thrombosis and pulmonary embolism, is a common problem associated with significant morbidity, mortality, and resource expenditure. Unfractionated heparin, low-molecular-weight heparin, and vitamin K antagonists are the most common treatment and prophylaxis, and have demonstrated their efficacy in a vast number of previous studies. Despite their broad use, these agents have important limitations that have led to the development of new drugs in a bid to overcome the disadvantages of the old ones without decreasing their therapeutic effect. These novel medications, some approved and others in different stages of development, include direct thrombin inhibitors like dabigatran etexilate, and direct activated factor X inhibitors like rivaroxaban. The current paper will review the characteristics, clinical trial results, and current and potential therapeutic uses of these new agents with a focus on the categories of direct thrombin inhibitors and activated factor X inhibitors.http://dx.doi.org/10.1155/2012/856341 |
| spellingShingle | Roberto C. Montoya Ajeet Gajra Current Status of New Anticoagulants in the Management of Venous Thromboembolism Advances in Hematology |
| title | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
| title_full | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
| title_fullStr | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
| title_full_unstemmed | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
| title_short | Current Status of New Anticoagulants in the Management of Venous Thromboembolism |
| title_sort | current status of new anticoagulants in the management of venous thromboembolism |
| url | http://dx.doi.org/10.1155/2012/856341 |
| work_keys_str_mv | AT robertocmontoya currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism AT ajeetgajra currentstatusofnewanticoagulantsinthemanagementofvenousthromboembolism |